Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial brillation. N Engl J Med 2011;365:883 91. 217. Dries DL, Rosenberg YD, Waclawiw MA, et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997;29:1074 80. 218. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial brillation: the Task Force for the Management of Atrial Fibril- lation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369 429. 219. Freudenberger RS, Hellkamp AS, Halperin JL, et al. Risk of thrombo- embolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2007;115:2637 41. 220. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251 7. 221. Massie BM, Collins JF, Ammon SE, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009;119:1616 24. 222. Homma S, Thompson JL, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012;366: 1859 69. 223. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004;43:642 8. 224. Anker SD, Clark AL, Winkler R, et al. Statin use and survival in patients with chronic heart failure: results from two observational studies with 5200 patients. Int J Cardiol 2006;112:234 42. 225. Go AS, Lee WY, Yang J, et al. Statin therapy and risks for death and hospitalization in chronic heart failure. 